

## EQA round: BIL2/24 - Bilirubin Neonatal

Deadline: 23.8.2024

Setup: groups - M (measurement principle); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	CVPG = consensus of the participants' groups	UL = upper limit
N <sub>tot</sub> = total number of the results	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability						N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(215) Bilirubin total</b>	[μmol/L]				119								119	111	93
<b>Sample A</b>		322	25	7,7	119		CVP	322	5,6	18%	264	380	119	112	94
(1) Jendrassik - Gróf		332	15	4,6	7	0							7		
(2) DCA, DPD		313	16	5,1	92	0							92		
(7) Oxidation-reduction methods		369	19	5,1	18	0							18		
Other					2	0							2		
							1x 3, 1x 5								
<b>Sample B</b>		205	16	8	119		CVP	205	3,7	18%	168	242	119	113	95
(1) Jendrassik - Gróf		212	3,9	1,8	7	0							7		
(2) DCA, DPD		199	11	5,4	92	0							92		
(7) Oxidation-reduction methods		231	13	5,6	18	0							18		
Other					2	0							2		
							1x 3, 1x 5								
<b>(216) Bilirubin direct</b>	[μmol/L]				106								102	99	97
<b>Sample A</b>		52,6	9,8	19	106								102	99	97
(1) Jendrassik - Gróf; (60) Roche		47,9	7	15	5	0	CVPG	47,2	2,2	18%	38,7	55,7	5		
(2) DCA, DPD; (1) Abbott		45,5	1,3	2,9	14	0	CVPG	45,5	0,98	18%	37,3	53,7	14		
(2) DCA, DPD; (58) Beckman Coulter (AU)		67,4	4,6	6,8	23	0	CVPG	67,4	2,3	18%	55,2	79,6	23		
(2) DCA, DPD; (60) Roche		47,3	5,7	12	37	0	CVPG	47,2	2,2	18%	38,7	55,7	37		
(7) Oxidation-reduction methods; (162) Siemens (Atellica)		54,8	4,8	8,7	12	0	CVPG	55,1	3	18%	45,1	65,1	12		
(7) Oxidation-reduction methods; (179) Siemens		54,7	1,9	3,5	5	0	CVPG	54,7	5,4	18%	44,8	64,6	5		
Other					10	0							6		
							1x 0/0, 2x 1/1, 1x 1/158, 3x 2/162, 1x 7/70, 1x 7/77, 1x 99/60								
<b>Sample B</b>		36,7	7,8	21	106								102	101	99
(1) Jendrassik - Gróf; (60) Roche		32,7	4,9	15	5	0	CVPG	32,4	1,4	18%	26,5	38,3	5		
(2) DCA, DPD; (1) Abbott		30,4	1,4	4,6	14	0	CVPG	30,5	0,97	18%	25	36	14		
(2) DCA, DPD; (58) Beckman Coulter (AU)		48,7	3,2	6,5	23	0	CVPG	48,7	1,6	18%	39,9	57,5	23		
(2) DCA, DPD; (60) Roche		32,4	3,8	12	37	0	CVPG	32,4	1,4	18%	26,5	38,3	37		
(7) Oxidation-reduction methods; (162) Siemens (Atellica)		39	3,7	9,5	12	0	CVPG	38,8	2	18%	31,8	45,8	12		
(7) Oxidation-reduction methods; (179) Siemens		38,6	2,1	5,4	5	0	CVPG	38,6	5,9	18%	31,6	45,6	5		
Other					10	0							6		
							1x 0/0, 2x 1/1, 1x 1/158, 3x 2/162, 1x 7/70, 1x 7/77, 1x 99/60								